Abstract: Drug-induced thrombocytopenia can be detected via the use of an enzyme-linked immunospecific assay.

Abstract: A blood gas-hemoglobin analysis control which simulates whole human blood characteristics comprising a buffered suspension medium containing erythrocytes which have been stabilized with an imidoester protein cross-linking agent while being contacted with a gas consisting of pure oxygen or pure carbon monoxide.

Abstract: The invention relates to a process for preparing substituted polycyclo-alkylidene polycyclo-alkanes, such as substituted adamantylidene adamantanes, and the corresponding epidioxy compounds, in which polycyclo-alkylidene polycyclo-alkanes are halogenated with an N-halosuccinimide, tert.-butylhypohalite or sodium hypohalite/CH.sub.3 COOH, the halogenation product is optionally subjected to a substitution reaction, and the substituted polycycloalkylidene polycyclo-alkanes are converted to the corresponding epidioxy compounds in a way known per se.Further, the invention relates to compounds of formula 44 ##STR1## in which A and B represent alkylene radicals, which alkylene radicals may be attached to each other via an alkylene radical C, and R.sub.1 represents a substituent, which, in case of 4-eq.-R.sub.1 -2,2'-adamantylidene adamantane cannot be chloro, hydroxy, oxo, D or a group of formula 1: ##STR2## as well as to compounds of formula 45: ##STR3## in which A, B and C are as defined above, and R.sub.

Abstract: The invention relates to compounds of the general formula I ##STR1## wherein R.sub.1 represents one up to and including four, the same or different substituents selected from alkyl(1-6 C), alkoxy(1-6 C), hydroxy, halogen, NO.sub.2, CF.sub.3 or the group --NR.sub.5 R.sub.6,whereby two substituents taken together may also represent a methylene-dioxy group,X represents a member selected from ##STR2## --CH.sub.2 --CH.sub.2 -- and --CH.dbd.CH--, n has the value 0, 1 or 2,R.sub.3 represents one of the moieties: ##STR3## and R.sub.2, R.sub.4, R.sub.5 and R.sub.6 represent hydrogen or alkyl(1-6 C),and pharmaceutically acceptable salts thereof, suitable in the treatment of heartfailure.

Abstract: The present invention concerns a method for detection of the core antigen of hepatitis B virus in a sample comprising a first incubation with carrier-bound antibodies directed against hepatitis B surface antigens and a second incubation with antibodies against the core antigen in the presence of a detergent.Also claimed are test kits for carrying out this method and an immunochemical reagent comprising antibodies directed against the surface antigen and against the core antigen conjointly bound to a carrier.

Abstract: The invention comprises an assembly of an intra-uterine contraceptive device and an insertor, whereby the contraceptive device is provided with a central stem and two or more flexible self-supporting arms; at least the said stem is accommodated in the insertor, and said insertor is at one end, over some distance, opened to form a groove or half-cylinder in such a way that the stem of the contraceptive device can be introduced and removed therefrom, said half-cylinder portion ending into a knob or thickening.

Abstract: There is provided an improved system for controlling ultrafiltration in hemodialysis which is independent of the membrane used in the dialyzer. A load cell measures the instantaneous amounts of fluid in a reservoir which receives fluids from the dialyzer and feeds this information into an electronic controller which has been programmed for the desired ultrafiltration. The controller generates an error signal and controls a negative pressure control valve which, in turn, determines the rate and thus amount of ultrafiltration.

Abstract: Partial thromboplastin time (PTT) is determined for monitoring and controlling heparin therapy with a test kit having increased sensitivity to heparin. Increased sensitivity is obtained by including with reagents in the test kit an organic sulfuric acid or salt thereof such as dodecylbenzenesulfuric acid--sodium salt and/or an organic sulfuric acid ester or salt thereof such as sodium laurylsulfate.

Abstract: A drug delivery system in the form of dosage units for controlled release of active material comprising a core and a coating layer enclosing said core.The coating material contains a microporous synthetic thermoplastic polymer and is compressed into a suitable coating layer enclosing the core with the aid of relatively low compression forces.

Abstract: The invention is dealing with antispasmodic compounds of the formula I ##STR1## in which R.sub.1 denotes H, halogen or a linear or branched C.sub.1 to C.sub.3 alkoxy or alkyl group, R.sub.2, R.sub.3 and R.sub.4 separately denote a linear or branched C.sub.1 to C.sub.4 alkyl group or R.sub.2 and R.sub.3 together with the nitrogen atom to which they are bound form a saturated heterocyclic radical, Z denotes a linear or branched C.sub.1 to C.sub.6 alkylene group and X.sup.- denotes an anion, preferably a halogen ion,and is dealing with intermediates in the preparation of the compounds of formula I.